[HTML][HTML] SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19
V Glück, S Grobecker, L Tydykov, B Salzberger… - Infection, 2021 - Springer
V Glück, S Grobecker, L Tydykov, B Salzberger, T Glück, T Weidlich, M Bertok, C Gottwald…
Infection, 2021•SpringerObjective To follow serological immune responses of front-line healthcare workers after PCR-
confirmed COVID-19 for a mean of 30 weeks, describe the time-course of SARS-CoV-2
spike protein-specific IgG, IgA and IgM levels and to identify associations of the immune
response with symptoms, demographic parameters and severity of disease. Methods Anti-
SARS-CoV-2 S protein-specific IgG, IgA and IgM antibodies were measured at three time
points during the 30-week follow-up. COVID-19-specific symptoms were assessed with …
confirmed COVID-19 for a mean of 30 weeks, describe the time-course of SARS-CoV-2
spike protein-specific IgG, IgA and IgM levels and to identify associations of the immune
response with symptoms, demographic parameters and severity of disease. Methods Anti-
SARS-CoV-2 S protein-specific IgG, IgA and IgM antibodies were measured at three time
points during the 30-week follow-up. COVID-19-specific symptoms were assessed with …
Objective
To follow serological immune responses of front-line healthcare workers after PCR-confirmed COVID-19 for a mean of 30 weeks, describe the time-course of SARS-CoV-2 spike protein-specific IgG, IgA and IgM levels and to identify associations of the immune response with symptoms, demographic parameters and severity of disease.
Methods
Anti-SARS-CoV-2 S protein-specific IgG, IgA and IgM antibodies were measured at three time points during the 30-week follow-up. COVID-19-specific symptoms were assessed with standardized questionnaires.
Results
95% of the participants mounted an IgG response with only modest decline after week 12. IgG-type antibodies were still detectable in almost 90% of the subjects at 30 weeks. IgA and IgM responses were less robust and antibody titers decreased more rapidly. At 30 weeks, only 25% still had detectable IgA-type and none had IgM-type antibodies. Higher age and higher disease severity were independently associated with higher IgG antibody levels, albeit with wide variations.
Conclusion
Serological immune responses after COVID-19 show considerable inter-individual variability, but show an association with increasing age and higher severity of disease. IgG-type anti-SARS-CoV-2 antibodies remain positive in 90% of the individuals 30 weeks after onset of symptoms.
Springer